Phosphaturic Mesenchymal Tumor with Symptoms Related to Osteomalacia that Appeared One Year after Tumorectomy

Abstract

A 45-year-old

Curative surgical treatment after inefficient long-acting somatostatin analogues therapy of a tumor-induced osteomalacia

“…Seufert used subcutaneous octreotide during 13 days (50 mg three times a day on days 1 through 5 and 100 mg three times a day on days 6 through 13), and this therapy led to normalization of serum phosphorus levels, phosphate clearance, and the threshold for renal tubular reabsorption of phosphate [10]. Yoshioka et al treated a patient with subcutaneous octreotide during 7 days (100 mg three times a day), but did not observe any effect on the biochemical nor clinical parameters [16]. Paglia et al described a case in which intravenous octreotide was used during 6 days (600 mg per day), without any improvement in serum phosphorus level [17].…”

Tumor-Induced Hypophosphatemic Osteomalacia Diagnosed by the Combinatory Procedures of Magnetic Resonance Imaging and Venous Sampling for FGF23

“…3) (8), it failed to detect the tumor in this case. Scintigraphy using octreotide is also a useful method for detecting the tumor, although the efficacy of octreotide in the treatment of TIO remains controversial (9)(10)(11). However, this procedure has not been approved in Japan.…”

Definitive surgical treatment of osteomalacia induced by skull base tumor and determination of the half-life of serum fibroblast growth factor 23

“…Intracranial FGF23-producing PMTMCT is extremely rare and, to the best of our knowledge, only 17 cases have been reported in the literature to date (Table 1) [6][7][8][9][10][11][12][13][14][15][16][17][18][19][20]. It tends to affect sterically complicated areas such as the anterior skull base.…”